Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,059.10 +40.71 (+0.81%) Dow
38,187.59 +284.30 (+0.75%) Nasdaq
15,819.54 +214.06 (+1.37%) Bitcoin USD
59,086.38 +1,367.27 (+2.37%) CMC Crypto 200
1,279.01 +8.27 (+0.65%)
Athira Pharma, Inc. (ATHA)
| Previous close | 2.0400 |
| Open | 2.0566 |
| Bid | 1.9100 x 100 |
| Ask | 2.0300 x 100 |
| Day's range | 1.9500 - 2.0566 |
| 52-week range | 1.3300 - 4.2980 |
| Volume | |
| Avg. volume | 351,786 |
| Market cap | 75.695M |
| Beta (5Y monthly) | 2.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Athira Pharma to Participate in Upcoming May Conferences
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May. Sidoti May 2024 Virtual Investor ConferenceFormat: Company PresentationDate and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET Location: Virtual Th
- GlobeNewswire
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercializationBOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 ye
- GlobeNewswire
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s diseaseBOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s di
